SUBSCRIBE
SUBSCRIBE
News   Business

Regeneron Pharmaceuticals, Inc. Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement With Novartis Pharma AG

June 11, 2009 | 
1 min read
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that it has entered into two royalty agreements with Novartis Pharma AG that replace a previous collaboration and license agreement.
Alliances
Regeneron Pharmaceuticals, Inc.
MORE ON THIS TOPIC
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Mergers & acquisitions
Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm
July 16, 2025
 · 
1 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Ventus “Recalibrates” to Support Mid-Stage Trials
July 16, 2025
 · 
159 min read
 · 
BioSpace Editorial Staff
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
 · 
1 min read
 · 
Heather McKenzie
World Management Team in office silhouette 3d rendering
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
 · 
6 min read
 · 
Lori Ellis